title: "Is there any association between insulin resistance and thyroid cancer? : A case control study".
abstract: Insulin stimulates proliferation of thyroid cells in culture. The presence of insulin resistance (IR) is associated with larger thyroid gland volume and an increased prevalence of thyroid nodules. The aim of this study was to investigate the presence of any possible association between IR and thyroid cancer. Forty-one patients with diffuse thyroid cancer (Group 1) were matched for age and gender with 41 patients with nodular goiter (Group 2). Both groups were compared in terms of frequency of IR, as estimated by the homeostasis model assessment, as well as other parameters of the metabolic syndrome (MetS). Fourteen patients (34.1 %) in each group had MetS. Twelve patients (29.3 %) in group 1 had IR compared to 10 (24.4 %) in group 2. Mean HOMA-IR scores in group 1 and 2 were 2.5 ± 2.2 and 1.8 ± 1.1, respectively. Thirty-two patients (78 %) in group 1 had a body mass index (BMI) of more than 25 compared to 33 patients (80.5 %) in group 2. The difference between groups with regard to HOMA-IR, the frequency of IR, BMI, and any of the parameters of MetS was statistically insignificant (p > 0.05). A subgroup analysis based on tumor size did not reveal a significant difference between patients with microcarcinoma (≤10 mm) and macrocarcinoma (>10 mm) in terms of any of the study parameters (p > 0.05). Neither MetS nor IR was a significant risk factor for thyroid cancer following logistic regression analysis (p > 0.05). IR is not more prevalent in patients with thyroid cancer. Some other pathologic mechanisms may be more prominent during thyroid carcinogenesis.
authors.affiliation: Department of Endocrinology and Metabolism, Yildirim Beyazit University Medical School Ataturk Teaching and Research Hospital, Bilkent, Ankara, Turkey, fevzi.balkan@yahoo.com.
authors.forename: Fevzi
authors.initials: F
authors.lastname: Balkan
authors.forename: Eda Demir
authors.initials: ED
authors.lastname: Onal
authors.forename: Alper
authors.initials: A
authors.lastname: Usluogullari
authors.forename: Dilek
authors.initials: D
authors.lastname: Tuzun
authors.forename: Didem
authors.initials: D
authors.lastname: Ozdemir
authors.forename: Serap Soytac
authors.initials: SS
authors.lastname: Inancli
authors.forename: Reyhan
authors.initials: R
authors.lastname: Ersoy
authors.forename: Bekir
authors.initials: B
authors.lastname: Cakir
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000453:epidemiology; D005260:Female; D006801:Humans; D006965:Hyperplasia / Q000453:epidemiology; D007333:Insulin Resistance / Q000502:physiology*; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications / Q000453:epidemiology; D008875:Middle Aged; D012307:Risk Factors; D013961:Thyroid Gland / Q000473:pathology; D013964:Thyroid Neoplasms / Q000453:epidemiology* / Q000209:etiology*; D016606:Thyroid Nodule / Q000453:epidemiology / Q000473:pathology; D055815:Young Adult
references.citation: PLoS One. 2012;7(12):e53096
references.pmid: 23300866
references.citation: Aging (Albany NY). 2012 Sep;4(9):580-9
references.pmid: 22983440
references.citation: Prostate Cancer Prostatic Dis. 2000 Nov;3(3):157-172
references.pmid: 12497092
references.citation: Gen Physiol Biophys. 2009 Dec;28(4):363-70
references.pmid: 20097959
references.citation: J Urol. 2004 Feb;171(2 Pt 2):S36-40
references.pmid: 14713751
references.citation: Endocr Relat Cancer. 2009 Dec;16(4):1103-23
references.pmid: 19620249
references.citation: Dtsch Med Wochenschr. 1981 Oct 9;106(41):1338-40
references.pmid: 7274082
references.citation: PLoS Med. 2009 Dec;6(12):e1000201
references.pmid: 20027213
references.citation: Cancer Res. 2010 Nov 1;70(21):8587-97
references.pmid: 20847342
references.citation: Endocrine. 2013 Aug;44(1):158-64
references.pmid: 23288662
references.citation: Br Med Bull. 1989 Apr;45(2):465-80
references.pmid: 2480830
references.citation: J Natl Cancer Inst. 2007 Nov 7;99(21):1594-602
references.pmid: 17971526
references.citation: J Bone Miner Res. 2007 Dec;22 Suppl 2:V81-5
references.pmid: 18290728
references.citation: Cancer Causes Control. 2009 Jul;20(5):525-31
references.pmid: 19016336
references.citation: Metab Syndr Relat Disord. 2009 Aug;7(4):375-80
references.pmid: 19320560
references.citation: Thyroid. 2011 Sep;21(9):957-63
references.pmid: 21767143
references.citation: Mol Cell Endocrinol. 1999 May 25;151(1-2):103-19
references.pmid: 10411325
references.citation: Best Pract Res Clin Endocrinol Metab. 2007 Jun;21(2):173-91
references.pmid: 17574002
references.citation: Endocrine. 2012 Oct;42(2):229-30
references.pmid: 22736408
references.citation: Endocrine. 2012 Oct;42(2):382-90
references.pmid: 22315013
references.citation: Adv Exp Med Biol. 2008;624:31-42
references.pmid: 18348445
references.citation: Thyroid. 2008 Apr;18(4):461-4
references.pmid: 18346005
references.citation: Int J Surg. 2010;8(3):186-93
references.pmid: 20097316
references.citation: Cancer. 2006 Jul 1;107(1):28-36
references.pmid: 16721800
references.citation: Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1092-100
references.pmid: 19293311
references.citation: Eur J Endocrinol. 2009 Oct;161(4):599-605
references.pmid: 19633072
references.citation: Diabetes. 1988 Dec;37(12):1595-607
references.pmid: 3056758
references.citation: Diabetologia. 1985 Jul;28(7):412-9
references.pmid: 3899825
references.citation: Curr Diabetes Rev. 2005 May;1(2):137-43
references.pmid: 18220589
references.citation: J Urol. 2004 Nov;172(5 Pt 2):S6-11; discussion S11-2
references.pmid: 15535435
references.citation: Am J Epidemiol. 2006 Oct 15;164(8):769-74
references.pmid: 16952929